Literature DB >> 15915462

Molecular analysis of HLA class II associations with hepatitis B virus clearance and vaccine nonresponsiveness.

Andrew Godkin1, Miles Davenport, Adrian V S Hill.   

Abstract

Clearance of acute hepatitis B virus (HBV) infection is associated with a vigorous CD4+ T-cell response focusing on the core protein. HLA class II glycoproteins present viral peptides to CD4+ T cells and influence the immune responses. HLA-DRB1*1301/2 have been associated with viral clearance, and HLA-DRB1*0301 is associated with nonresponse to vaccination with envelope proteins. Binding affinities of overlapping peptides covering the core and envelope proteins of HBV were measured to HLA glycoproteins encoded by HLA-DRA1*0101,-DRB1*0101 (HLA-DR1), HLA-DRA1*0101,-DRB1*0301 (HLA-DR3), HLA-DRA1*0101,-DRB1*0701 (HLA-DR7) and HLA-DRA1*0101,-DRB1*1301 (HLA-DR13) molecules and compared with published peptide-specific CD4+ T-cell responses. There are more high-affinity ligands (IC50 < 1 micromol/L) derived from the core protein than the surface antigen (P < .04 for HLA-DR1/7/13), but there was no increase in the number or the affinity of ligands for HLA-DR13. Clusters of particular core peptides bound to multiple HLA types, explaining the immunodominance of these regions for T-cell responses. Within the envelope protein, the low-affinity ligands (IC50 < 10 micromol/L) are found mainly in the surface antigen, with a marked paucity of ligands for HLA-DR3 (HLA-DR3 vs. non-DR3; P < .05) consistent with the lower vaccination responses for this HLA type. Of all peptides tested, 8 to 10 bound mainly to one HLA type, allowing a substantially greater breadth of response in heterozygotes. In conclusion, these data offer a mechanistic explanation for the dominant response to the HBV core protein during infection and support the direct involvement of the HLA-DRB1 gene in vaccine nonresponsiveness but not altered susceptibility to viral persistence.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15915462     DOI: 10.1002/hep.20716

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  42 in total

1.  Strong influence of human leukocyte antigen (HLA)-DP gene variants on development of persistent chronic hepatitis B virus carriers in the Han Chinese population.

Authors:  Xiuchan Guo; Yong Zhang; Ji Li; Jingchen Ma; Zuli Wei; Wenjie Tan; Stephen J O'Brien
Journal:  Hepatology       Date:  2011-01-04       Impact factor: 17.425

2.  Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota.

Authors:  Han-Hsuan Chou; Wei-Hung Chien; Li-Ling Wu; Chi-Hung Cheng; Chen-Han Chung; Jau-Haw Horng; Yen-Hsuan Ni; Hong-Tai Tseng; Dafei Wu; Xuemei Lu; Hurng-Yi Wang; Pei-Jer Chen; Ding-Shinn Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-02       Impact factor: 11.205

3.  Impaired hepatitis B vaccine responses during chronic hepatitis C infection: involvement of the PD-1 pathway in regulating CD4(+) T cell responses.

Authors:  Jonathan P Moorman; Chun L Zhang; Lei Ni; Cheng J Ma; Ying Zhang; Xiao Y Wu; Penny Thayer; Tareq M Islam; Thomas Borthwick; Zhi Q Yao
Journal:  Vaccine       Date:  2011-03-03       Impact factor: 3.641

Review 4.  Hepatitis B vaccine in celiac disease: yesterday, today and tomorrow.

Authors:  Giovanna Vitaliti; Andrea Domenico Praticò; Carla Cimino; Giovanna Di Dio; Elena Lionetti; Mario La Rosa; Salvatore Leonardi
Journal:  World J Gastroenterol       Date:  2013-02-14       Impact factor: 5.742

5.  Host susceptibility to persistent hepatitis B virus infection.

Authors:  Ying-Li He; Ying-Ren Zhao; Shu-Lin Zhang; Shu-Mei Lin
Journal:  World J Gastroenterol       Date:  2006-08-14       Impact factor: 5.742

6.  Association of TNF-α Promoter Polymorphism with HBV Associated Disease Outcome Among HBV Infected Patients from Orissa, Southern Part of East India.

Authors:  Rajesh Panigrahi; Neelakshi Sarkar; Avik Biswas; Ananya Pal; Debraj Saha; Shivaram P Singh; Manas K Panigrahi; Manikanana Bandopadhyay; Sekhar Chakrabarti; Runu Chakravarty
Journal:  J Clin Exp Hepatol       Date:  2014-09-18

7.  KLRG1 impairs CD4+ T cell responses via p16ink4a and p27kip1 pathways: role in hepatitis B vaccine failure in individuals with hepatitis C virus infection.

Authors:  Lei Shi; Jia M Wang; Jun P Ren; Yong Q Cheng; Ruo S Ying; Xiao Y Wu; Shu M Lin; Jeddidiah W D Griffin; Guang Y Li; Jonathan P Moorman; Zhi Q Yao
Journal:  J Immunol       Date:  2013-12-13       Impact factor: 5.422

8.  Normal or defective immune response to Hepatitis B vaccine in patients with diabetes and celiac disease.

Authors:  Giovanna Zanoni; Giovanna Contreas; Enrico Valletta; Oretta Gabrielli; Carlo Mengoli; Dino Veneri
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

9.  Partial delipidation improves the T-cell antigenicity of hepatitis B virus surface antigen.

Authors:  Isabelle Desombere; Annick Willems; Yvonne Gijbels; Geert Leroux-Roels
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

10.  Intramuscular vs intradermal route for hepatitis B booster vaccine in celiac children.

Authors:  Salvatore Leonardi; Andrea Domenico Praticò; Elena Lionetti; Massimo Spina; Giovanna Vitaliti; Mario La Rosa
Journal:  World J Gastroenterol       Date:  2012-10-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.